The new solution, QTinno is intended to be used for an upcoming Thorough QT trial.
According to the company, QTinno 3-D ECG software technology is a novel, fully automated program for evaluating QT and other timing intervals relevant for assessing drug cardiac toxicity in drug development.
NewCardio COO Greg Sadowski said the company is pleased to participate in the TQT trial for a biotech company with their CRO partner.
"QTinno’s selection for this study, based on the performance in prior studies, provides clear evidence of the pharmaceutical company’s confidence, not only in the accuracy and precision of QTinno’s fully automated ECG analysis, but also in the FDA’s willingness to accept drug safety data from properly validated technology such as QTinno," Sadowski added.